| Acceptance rate | 46% |
|---|---|
| Time to first decision | 20 days* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2020 , Vol 58 , Num 4
Molecular Drug Design and Docking Study of Novel N- substituted Celecoxib Derivatives as Selective Cyclooxygenase-2 Inhibitors
1 College of Education for Women, University of Anbar, Department of Chemistry, Ramadi, Iraq2 College of Pharmacy, Mustansiriyah University, Department of Pharmaceutical Chemistry, Baghdad, Iraq
DOI : 10.23893/1307-2080.APS.05823 Celecoxib is one of the best potent nonsteroidal anti-inflammatory drug (NSAID) used as cyclooxygenase-2 (COX-2) selective inhibitor. For decades it effectively used in pain and inflammation treatment because the ability of reducing prostaglandin (PG) synthesis by obstruct the transformation of arachidonic acid to PGH2. But several serious side effects synchronized includes kidney failure, nausea, gastrointestinal tract bleeding, myocardial infarction, abdominal pain, and finally diarrhea. In this paper, a total of 155 Celecoxib derivatives were successfully docked inside crystal structure of cyclooxygenase-2 (COX-2) enzyme to estimate the potency of each derivative to bind inside active site. The highest twenty effective derivatives were recorded with docking score range of (-16.997 to -14.611) kcal/mol. Keywords : Drug Design, Docking Study, Scaffold hopping